{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T22:02:22Z","timestamp":1753740142232},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T00:00:00Z","timestamp":1411603200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Retrovirology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s12977-014-0079-7","type":"journal-article","created":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T15:18:45Z","timestamp":1411571925000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes"],"prefix":"10.1186","volume":"11","author":[{"given":"Guangdi","family":"Li","sequence":"first","affiliation":[]},{"given":"Jens","family":"Verheyen","sequence":"additional","affiliation":[]},{"given":"Kristof","family":"Theys","sequence":"additional","affiliation":[]},{"given":"Supinya","family":"Piampongsant","sequence":"additional","affiliation":[]},{"given":"Kristel","family":"Van Laethem","sequence":"additional","affiliation":[]},{"given":"Anne-Mieke","family":"Vandamme","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,9,25]]},"reference":[{"key":"79_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/QAD.0b013e32835a10d8","volume":"27","author":"L Larrouy","year":"2013","unstructured":"Larrouy L, Vivot A, Charpentier C, Benard A, Visseaux B, Damond F, Matheron S, Chene G, Brun-Vezinet F, Descamps D: Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients. AIDS. 2013, 27: 69-80. 10.1097\/QAD.0b013e32835a10d8.","journal-title":"AIDS"},{"key":"79_CR2","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1128\/AAC.00194-10","volume":"54","author":"L Larrouy","year":"2010","unstructured":"Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, Collin G, Charpentier C, Storto A, Pialoux G, Katlama C, Girard PM, Yeni P, Aboulker JP, Brun-Vezinet F, Descamps D, Group AS: Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive HIV-infected patients. Antimicrob Agents Chemother. 2010, 54: 2910-2919. 10.1128\/AAC.00194-10.","journal-title":"Antimicrob Agents Chemother"},{"key":"79_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.antiviral.2009.10.003","volume":"85","author":"AM Wensing","year":"2010","unstructured":"Wensing AM, van Maarseveen NM, Nijhuis M: Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Res. 2010, 85: 59-74. 10.1016\/j.antiviral.2009.10.003.","journal-title":"Antiviral Res"},{"key":"79_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1742-4690-9-63","volume":"9","author":"A Fun","year":"2012","unstructured":"Fun A, Wensing AM, Verheyen J, Nijhuis M: Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology. 2012, 9: 63-10.1186\/1742-4690-9-63.","journal-title":"Retrovirology"},{"key":"79_CR5","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1097\/QAD.0b013e32834cabb9","volume":"25","author":"L Larrouy","year":"2011","unstructured":"Larrouy L, Charpentier C, Landman R, Capitant C, Chazallon C, Yeni P, Peytavin G, Damond F, Brun-Vezinet F, Descamps D: Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen. AIDS. 2011, 25: 2143-2148. 10.1097\/QAD.0b013e32834cabb9.","journal-title":"AIDS"},{"key":"79_CR6","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1097\/QAD.0b013e3283398216","volume":"24","author":"RK Gupta","year":"2010","unstructured":"Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D, Parry CM: Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. AIDS. 2010, 24: 1651-1655. 10.1097\/QAD.0b013e3283398216.","journal-title":"AIDS"},{"key":"79_CR7","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/QAD.0b013e328336784d","volume":"24","author":"E Knops","year":"2010","unstructured":"Knops E, Kemper I, Schulter E, Pfister H, Kaiser R, Verheyen J: The evolution of protease mutation 76 V is associated with protease mutation 46I and gag mutation 431 V. AIDS. 2010, 24: 779-781. 10.1097\/QAD.0b013e328336784d.","journal-title":"AIDS"},{"key":"79_CR8","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1089\/08892220050116970","volume":"16","author":"F Bally","year":"2000","unstructured":"Bally F, Martinez R, Peters S, Sudre P, Telenti A: Polymorphism of HIV type 1 gag p7\/p1 and p1\/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses. 2000, 16: 1209-1213. 10.1089\/08892220050116970.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"79_CR9","doi-asserted-by":"publisher","first-page":"e24798","DOI":"10.1371\/journal.pone.0024798","volume":"6","author":"J Ghosn","year":"2011","unstructured":"Ghosn J, Delaugerre C, Flandre P, Galimand J, Cohen-Codar I, Raffi F, Delfraissy JF, Rouzioux C, Chaix ML: Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir\/ritonavir single drug regimen. PLoS One. 2011, 6: e24798-10.1371\/journal.pone.0024798.","journal-title":"PLoS One"},{"key":"79_CR10","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/jac\/dkq129","volume":"65","author":"E Knops","year":"2010","unstructured":"Knops E, Daumer M, Awerkiew S, Kartashev V, Schulter E, Kutsev S, Brakier-Gingras L, Kaiser R, Pfister H, Verheyen J: Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates. J Antimicrob Chemother. 2010, 65: 1472-1476. 10.1093\/jac\/dkq129.","journal-title":"J Antimicrob Chemother"},{"key":"79_CR11","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1089\/aid.2012.0311","volume":"29","author":"AH Rossi","year":"2013","unstructured":"Rossi AH, Rocco CA, Mangano A, Sen L, Aulicino PC: Sequence variability in p6 gag protein and gag\/pol coevolution in human immunodeficiency type 1 subtype F genomes. AIDS Res Hum Retroviruses. 2013, 29: 1056-1060. 10.1089\/aid.2012.0311.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"79_CR12","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/bioinformatics\/btt162","volume":"29","author":"P Libin","year":"2013","unstructured":"Libin P, Beheydt G, Deforche K, Imbrechts S, Ferreira F, Van Laethem K, Theys K, Carvalho AP, Cavaco-Silva J, Lapadula G, Torti C, Assel M, Wesner S, Snoeck J, Ruelle J, De Bel A, Lacor P, De Munter P, Van Wijngaerden E, Zazzi M, Kaiser R, Ayouba A, Peeters M, de Oliveira T, Alcantara LC, Grossman Z, Sloot P, Otelea D, Paraschiv S, Boucher C, Camacho RJ, Vandamme AM: RegaDB: community-driven data management and analysis for infectious diseases. Bioinformatics. 2013, 29: 1477-1480. 10.1093\/bioinformatics\/btt162.","journal-title":"Bioinformatics"},{"key":"79_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jviromet.2005.10.008","volume":"132","author":"K Van Laethem","year":"2006","unstructured":"Van Laethem K, Schrooten Y, Dedecker S, Van Heeswijck L, Deforche K, Van Wijngaerden E, Van Ranst M, Vandamme AM: A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes. J Virol Methods. 2006, 132: 181-186. 10.1016\/j.jviromet.2005.10.008.","journal-title":"J Virol Methods"},{"key":"79_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jviromet.2004.02.005","volume":"119","author":"B Maes","year":"2004","unstructured":"Maes B, Schrooten Y, Snoeck J, Derdelinckx I, Van Ranst M, Vandamme AM, Van Laethem K: Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory. J Virol Methods. 2004, 119: 45-49. 10.1016\/j.jviromet.2004.02.005.","journal-title":"J Virol Methods"},{"key":"79_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1742-4690-10-126","volume":"10","author":"G Li","year":"2013","unstructured":"Li G, Verheyen J, Rhee SY, Voet A, Vandamme AM, Theys K: Functional conservation of HIV-1 gag: implications for rational drug design. Retrovirology. 2013, 10: 126-10.1186\/1742-4690-10-126.","journal-title":"Retrovirology"},{"key":"79_CR16","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1086\/503914","volume":"42","author":"TF Liu","year":"2006","unstructured":"Liu TF, Shafer RW: Web resources for HIV type 1 genotypic-resistance test interpretation. Clinical infectious diseases. 2006, 42: 1608-1618. 10.1086\/503914.","journal-title":"Clinical infectious diseases"},{"key":"79_CR17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/135965350200700206","volume":"7","author":"K Van Laethem","year":"2002","unstructured":"Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, Vandamme AM: A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther. 2002, 7: 123-129.","journal-title":"Antivir Ther"},{"key":"79_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/1467-9868.00346","volume":"64","author":"JD Storey","year":"2002","unstructured":"Storey JD: A direct approach to false discovery rates. Journal of the Royal Statistical Society: Series B (Statistical Methodology). 2002, 64: 479-498. 10.1111\/1467-9868.00346.","journal-title":"Journal of the Royal Statistical Society: Series B (Statistical Methodology)"},{"key":"79_CR19","doi-asserted-by":"publisher","first-page":"9422","DOI":"10.1128\/JVI.77.17.9422-9430.2003","volume":"77","author":"T de Oliveira","year":"2003","unstructured":"de Oliveira T, Engelbrecht S, Janse van Rensburg E, Gordon M, Bishop K, zur Megede J, Barnett SW, Cassol S: Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?. J Virol. 2003, 77: 9422-9430. 10.1128\/JVI.77.17.9422-9430.2003.","journal-title":"J Virol"},{"key":"79_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1089\/aid.2010.0282","volume":"27","author":"AN Martins","year":"2011","unstructured":"Martins AN, Arruda MB, Pires AF, Tanuri A, Brindeiro RM: Accumulation of P(T\/S)AP late domain duplications in HIV type 1 subtypes B, C, and F derived from individuals failing ARV therapy and ARV drug-naive patients. AIDS Res Hum Retroviruses. 2011, 27: 687-692. 10.1089\/aid.2010.0282.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"79_CR21","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1128\/AAC.00690-06","volume":"51","author":"H Mo","year":"2007","unstructured":"Mo H, Parkin N, Stewart KD, Lu L, Dekhtyar T, Kempf DJ, Molla A: Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication. Antimicrob Agents Chemother. 2007, 51: 732-735. 10.1128\/AAC.00690-06.","journal-title":"Antimicrob Agents Chemother"},{"key":"79_CR22","doi-asserted-by":"publisher","first-page":"11027","DOI":"10.1128\/JVI.00628-09","volume":"83","author":"M Kolli","year":"2009","unstructured":"Kolli M, Stawiski E, Chappey C, Schiffer CA: Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J Virol. 2009, 83: 11027-11042. 10.1128\/JVI.00628-09.","journal-title":"J Virol"}],"container-title":["Retrovirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-014-0079-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12977-014-0079-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-014-0079-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-014-0079-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T19:10:59Z","timestamp":1650222659000},"score":1,"resource":{"primary":{"URL":"https:\/\/retrovirology.biomedcentral.com\/articles\/10.1186\/s12977-014-0079-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,25]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["79"],"URL":"https:\/\/doi.org\/10.1186\/s12977-014-0079-7","relation":{},"ISSN":["1742-4690"],"issn-type":[{"value":"1742-4690","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,25]]},"assertion":[{"value":"19 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"79"}}